NASDAQ:INVA - Innoviva Stock Price, Price Target & More

Innoviva trades on the NASDAQ under the ticker symbol "INVA."

Innoviva (NASDAQ:INVA) posted its earnings results on Thursday, April, 26th. The biotechnology company reported $0.27 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.50 by $0.23. The biotechnology company had revenue of $52.40 million for the quarter, compared to analysts' expectations of $71.84 million. Innoviva had a negative return on equity of 63.57% and a net margin of 64.11%. The company's revenue was up 29.4% compared to the same quarter last year. During the same period in the previous year, the company earned $0.19 earnings per share. View Innoviva's Earnings History.

Innoviva is scheduled to release their next quarterly earnings announcement on Tuesday, July, 24th 2018. View Earnings Estimates for Innoviva.

6 brokerages have issued 1-year target prices for Innoviva's shares. Their predictions range from $8.00 to $16.00. On average, they expect Innoviva's stock price to reach $13.20 in the next twelve months. View Analyst Ratings for Innoviva.

Innoviva saw a decrease in short interest during the month of April. As of April 30th, there was short interest totalling 11,842,171 shares, a decrease of 11.3% from the April 13th total of 13,344,078 shares. Based on an average daily volume of 1,262,701 shares, the short-interest ratio is presently 9.4 days. Approximately 17.7% of the shares of the company are sold short.

Some companies that are related to Innoviva include Ionis Pharmaceuticals (IONS), Catalent (CTLT), Loxo Oncology (LOXO), Agios Pharmaceuticals (AGIO), Galápagos (GLPG), Dr. Reddy's Laboratories (RDY), United Therapeutics (UTHR), Taro Pharmaceutical Industries (TARO), Hutchison China MediTech (HCM), GW Pharmaceuticals (GWPH), FibroGen (FGEN), Ligand Pharmaceuticals (LGND), Blueprint Medicines (BPMC), Array Biopharma (ARRY) and Ultragenyx Pharmaceutical (RARE).

Media stories about INVA stock have been trending somewhat positive recently, according to Accern Sentiment. The research group identifies negative and positive news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Innoviva earned a coverage optimism score of 0.18 on Accern's scale. They also assigned media coverage about the biotechnology company an impact score of 45.27 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.

Innoviva's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (10.68%), Dimensional Fund Advisors LP (1.69%), First Eagle Investment Management LLC (1.34%), Northern Trust Corp (1.01%), UBS Group AG (0.70%) and Victory Capital Management Inc. (0.63%). Company insiders that own Innoviva stock include Eric Desparbes, George B Abercrombie, Michael W Aguiar, Theodore J Jr Witek and Theodore L Witek Jr. View Institutional Ownership Trends for Innoviva.

INVA stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., BlackRock Inc., JPMorgan Chase & Co., Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp, Smith Asset Management Group LP, Systematic Financial Management LP, Camarda Financial Advisors LLC and Northern Trust Corp. Company insiders that have sold Innoviva company stock in the last year include Eric Desparbes, George B Abercrombie, Michael W Aguiar and Theodore J Jr Witek. View Insider Buying and Selling for Innoviva.

INVA stock was purchased by a variety of institutional investors in the last quarter, including UBS Group AG, Dimensional Fund Advisors LP, PNC Financial Services Group Inc., Millennium Management LLC, Hsbc Holdings PLC, Algert Global LLC, Hussman Strategic Advisors Inc. and A.R.T. Advisors LLC. View Insider Buying and Selling for Innoviva.

Shares of INVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of INVA stock can currently be purchased for approximately $14.59.

Innoviva has a market capitalization of $1.49 billion and generates $217.22 million in revenue each year. The biotechnology company earns $134.14 million in net income (profit) each year or $1.17 on an earnings per share basis. Innoviva employs 12 workers across the globe.

Innoviva's mailing address is 2000 SIERRA POINT PARKWAY SUITE 500, BRISBANE CA, 94005. The biotechnology company can be reached via phone at 650-238-9600 or via email at [email protected]